[go: up one dir, main page]

Pahl et al., 2018 - Google Patents

Memory-like NK cells: remembering a previous activation by cytokines and NK cell receptors

Pahl et al., 2018

View HTML
Document ID
8839928907381674515
Author
Pahl J
Cerwenka A
Ni J
Publication year
Publication venue
Frontiers in immunology

External Links

Snippet

Natural Killer (NK) cells are cytotoxic innate lymphoid cells serving at the front line against infection and cancer. In inflammatory microenvironments, multiple soluble and contact- dependent signals modulate NK cell responsiveness. Besides their innate cytotoxic and …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Similar Documents

Publication Publication Date Title
Pahl et al. Memory-like NK cells: remembering a previous activation by cytokines and NK cell receptors
Gardiner et al. What fuels natural killers? Metabolism and NK cell responses
Berrien-Elliott et al. Allogeneic natural killer cell therapy
Liu et al. NK cell-based cancer immunotherapy: from basic biology to clinical development
Kleinman et al. Regulatory T cells as potential targets for HIV cure research
Rovatti et al. Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation
Moro-García et al. Influence of inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, and oxidative changes
Knochelmann et al. CAR T cells in solid tumors: blueprints for building effective therapies
Chambers et al. Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells
Berrien-Elliott et al. Human cytokine-induced memory-like natural killer cells
EP3317399B1 (en) Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
Ye et al. The significance of tumor necrosis factor receptor type II in CD8+ regulatory T cells and CD8+ effector T cells
Granzin et al. Shaping of natural killer cell antitumor activity by ex vivo cultivation
Wu et al. γδ T cells and their potential for immunotherapy
Romee et al. Utilizing cytokines to function‐enable human NK cells for the immunotherapy of cancer
Geller et al. Use of allogeneic NK cells for cancer immunotherapy
Kennedy et al. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer
Kopp et al. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions
Jiang et al. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy
Li et al. Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection
EP3227435B1 (en) Gammadelta t cell expansion procedure
Domogala et al. Natural killer cell immunotherapy: from bench to bedside
Hippen et al. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease
Nanjireddy et al. Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes
Villalba et al. Non-genetically improving the natural cytotoxicity of natural killer (NK) cells